Teylor Martinez
Medical · Washington, DCNPI 1396361630
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,264 of the $5,872 with a category attached, or 89.7%. It is spread thinly across 53 manufacturers, the largest accounting for just 11.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,670 and has fallen 70.7% since, to $784 in 2025. Among medical clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 260 payments — averaging $22.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$683
- Novartis$489
- Merck$311
- AstraZeneca$282
- Gilead$281
- Pharmacyclics LLC, An Abbvie Company$260
- plus $4K from 47 others
What the payments were for
- Food & beverage$5,26490%
- Education$2745%
- Other$3336%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,872 in reported general payments places this provider in the 95th percentile of 87 medical providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anastrozole | 37 | $390 |
| Letrozole | 11 | $250 |
Paid to pharmacies, not to this prescriber.
Other medical in Washington
- Mariella PurvisWashington$13K
- Annise Williams-NairnWashington$8K
- Hannah SagedyWashington$5K
- Amanda-Gay EdwardsWashington$4K
- Albertina DearingWashington$4K
- Gwendolyn ChallengerWashington$4K
- Susan LelacheurWashington$4K
- Melanie Scott BowlingWashington$3K
- Connor ButzWashington$3K
- Samineh AsgariWashington$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.